Skip to main content

News

April 07, 2020
Don't miss this special live presentation on Managing Interventional Oncology in the Time of COVID-19, featuring insight by #CIO2020 Course Director, Edward Kim, MD.
August 19, 2019
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops and…
June 28, 2019
On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously…
June 26, 2019
WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.*…
June 11, 2019
Varian (NYSE: VAR) today announced it has acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer care solutions. Endocare is a leading provider of hardware and software…
April 16, 2019
Some patients who undergo selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) may be eligible for liver resection, researchers reported.
April 11, 2019
Researchers have identified factors that are linked with increased risk of symptomatic recurrence after radiofrequency ablation for osteoid osteomas.
April 09, 2019
The Society of Interventional Oncology (SIO) recently sent a letter to the National Comprehensive Cancer Network (NCCN) Kidney Cancer Guideline panel seeking changes to proposed guidelines for management of T1a renal masses.
April 04, 2019
In an abstracted presented at SIR, researchers evaluated whether transarterial Y-90 radioembolization with resin microspheres using MIRD dosimetry for intrahepatic cholangiocarcinoma is safe and effective.
March 28, 2019
Patients with metastatic neuroendocrine tumors may potentially be able to consider same-day mapping or no mapping prior to treatment with Y-90 radioembolization, according to an abstract presented at SIR.
March 26, 2019
In an abstract presented at SIR, researchers explained how a review and meta-analysis helps to better understand Y-90 radioembolization dosimetry and how dose relates to tumor response and hepatotoxicity.
Back to Top